ENDRA Life Sciences- Warrants (12/05/2022) Return on Equity

ENDRA Life Sciences- Warrants (12/05/2022) posts a ROE of -4.09%. That is below the Technology sector average of 47.22%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Technology stocks, a ROE near 47.22% is typical. ENDRA Life Sciences- Warrants (12/05/2022)'s -4.09% is lower that level. That is roughly 965.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

ENDRA Life Sciences- Warrants (12/05/2022)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -4.09%; use YoY and peer views to separate noise from signal.

Context for NDRAW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 47.22%), and (3) consistency with growth and profitability. This page covers the first two; ENDRA Life Sciences- Warrants (12/05/2022)'s other metric pages and overview cover the third.

Judging ENDRA Life Sciences- Warrants (12/05/2022) against Technology peers is usually better than using a market-wide rule of thumb. Business models inside Technology are more comparable, which makes gaps in ROE easier to interpret. Start with -4.09% here, then scan peer and history charts to see if the gap is persistent.